Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology... see more

Recent & Breaking News (TSX:CPH)

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

Canada NewsWire 3 days ago

Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment

Canada NewsWire May 8, 2025

Cipher Pharmaceuticals Schedules Q1 2025 Earnings Release and Conference Call

Canada NewsWire May 2, 2025

Cipher Pharmaceuticals Announces Normal Course Issuer Bid, Including Intention to Utilize Block Purchases

Canada NewsWire May 1, 2025

Cipher Pharmaceuticals' Natroba granted Medicaid preferred status in Illinois

Trevor Abes  April 29, 2025

Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba(TM) in the state of Illinois

Canada NewsWire April 29, 2025

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results

Canada NewsWire March 18, 2025

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call

Canada NewsWire March 11, 2025

Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study

Canada NewsWire December 10, 2024

Cipher Pharmaceuticals Reports Third Quarter 2024 Results

Canada NewsWire November 7, 2024

Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call

Canada NewsWire November 4, 2024

Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer

Canada NewsWire October 8, 2024

Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study

Canada NewsWire September 13, 2024

Canadian Investment Regulatory Organization Trade Resumption - CPH

Canada NewsWire September 13, 2024

Canadian Investment Regulatory Organization Trading Halt - CPH

Canada NewsWire September 13, 2024

Cipher Pharmaceuticals Reports Second Quarter 2024 Results

Canada NewsWire August 8, 2024

Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call

Canada NewsWire August 1, 2024

Cipher Pharmaceuticals acquires rights to dermatology products

Jocelyn Aspa July 29, 2024

Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million

Canada NewsWire July 29, 2024

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

Canada NewsWire June 14, 2024